Overview

* MiMedx ( MDXG ) Q2 net sales rise 13% yr/yr to $99 mln, beating analyst expectations

* Adjusted EBITDA for Q2 was $24 mln, or 25% of net sales

Outlook

* MiMedx ( MDXG ) expects 2025 net sales growth in low double-digits

* Company anticipates 2025 adjusted EBITDA margin above 20%

* MiMedx ( MDXG ) engaging with CMS on reimbursement reforms

Result Drivers

* WOUND PRODUCT SALES - Driven by 12% growth, supported by newer products CELERA™ and EMERGE™

* SURGICAL PRODUCT SALES - Increased 15% with contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™

* GROSS MARGIN DECLINE - Decrease attributed to production variances and product mix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $98.60 $90.60

mln mln (5

Analysts

)

Q2 EPS $0.06

Q2 Net $9.62

Income mln

Q2 Gross $79.92

Profit mln

Q2 $12.37

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for MiMedx Group Inc ( MDXG ) is $12.00, about 44.4% above its July 29 closing price of $6.67

* The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)